Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argent BiopharmaRGTLF EV-to-OCF is -1.68 as of Aug. 09, 2026. The stock has 8 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Argent Biopharma ranks better than 73.16% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Argent Biopharma's Enterprise Value is $8.39 Mil.
Argent Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.99 Mil. Therefore, Argent Biopharma's EV-to-OCF for today is -1.68.
The historical rank and industry rank for Argent Biopharma's EV-to-OCF or its related term are showing as below:
RGTLF'
s EV-to-OCF Range Over the Past 10 Years
Min: -21.33 Med: -3.66 Max: -0.06
Current: -1.57
During the past 13 years, the highest EV-to-OCF of Argent Biopharma was -0.06. The lowest was -21.33. And the median was -3.66.
RGTLF's EV-to-OCF is ranked better than 73.16% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.06
vs RGTLF: -1.57
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Argent Biopharma's PE Ratio (TTM) for today is calculated as:
Argent Biopharma's share price for today is $0.025.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.073.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Argent Biopharma EV-to-OCF Related Terms
Argent Biopharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's EV-to-OCF falls into.
Argent Biopharma's current Enterprise Value is $8.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (RGTLF) has a EV-to-OCF of -1.68 as of Aug. 09, 2026. According to the industry distribution chart, Argent Biopharma ranks #270 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Argent Biopharma's EV-to-OCF too high?
Argent Biopharma's current EV-to-OCF is -1.68. Based on the distribution chart, Argent Biopharma ranks #270 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Argent Biopharma's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #270 out of 1006 companies for EV-to-OCF. This puts Argent Biopharma in the upper half of its industry. The industry median EV-to-OCF is 11.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current EV-to-OCF is -1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Argent Biopharma (RGTLF) has a current EV-to-OCF of -1.68. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current EV-to-OCF is -1.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current EV-to-OCF is -1.68 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 
